- Trials with a EudraCT protocol (900)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
900 result(s) found for: Child Development.
Displaying page 1 of 45.
EudraCT Number: 2013-004444-31 | Sponsor Protocol Number: KWMP001 | Start Date*: 2015-01-09 |
Sponsor Name: | ||
Full Title: Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or... | ||
Medical condition: Prosepctive randomized two armed study to evaluate moderate depression during pregnancy treated with interbnetbased CBT and sertarline or placebo and longterm outcome in the children.Secondary obj... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004668-31 | Sponsor Protocol Number: SPD503-318 | Start Date*: 2012-03-14 | |||||||||||
Sponsor Name:Shire Pharmaceutical Development Ltd | |||||||||||||
Full Title: A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat... | |||||||||||||
Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) IE (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004489-23 | Sponsor Protocol Number: NVI-248 | Start Date*: 2008-10-20 |
Sponsor Name:Netherlands Vaccine Institute | ||
Full Title: Development of cellular immune response after infant pneumococcal conjugate vaccinations | ||
Medical condition: Cellular immune response(long term memory) after following the infant immunisation programme with a pneumococcal conjugate vaccine (Prevenar). | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-006161-11 | Sponsor Protocol Number: RC31/20/0421 | Start Date*: Information not available in EudraCT |
Sponsor Name: Toulouse University Hospital | ||
Full Title: LONG -TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH P... | ||
Medical condition: Prader-willi syndrome | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005523-27 | Sponsor Protocol Number: CIRROXABAN | Start Date*: 2015-07-30 |
Sponsor Name:INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS) | ||
Full Title: Multicenter prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis | ||
Medical condition: Liver cirrhosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000499-24 | Sponsor Protocol Number: 200722 | Start Date*: 2015-02-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies | |||||||||||||
Medical condition: preterm labour and improve neonatal health | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005480-28 | Sponsor Protocol Number: IJG-FER-2012 | Start Date*: 2013-05-21 |
Sponsor Name:Institut d?Investigació en Atenció Primaria IDIAP Jordi Gol | ||
Full Title: Effectiveness of adaptation of the dose of iron supplementation in pregnancy on maternal-child health. Randomized clinical trial (ECLIPSES) | ||
Medical condition: Pregnant women, less than 12 week of gestations,without anemia (Hb <110 d / dL) in the pre-analytical at 12 weeks | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000156-11 | Sponsor Protocol Number: S65914 | Start Date*: 2022-02-25 |
Sponsor Name:KU Leuven | ||
Full Title: Oxytocin and the development of attachment: Looking beyond the expected? | ||
Medical condition: General healthy population children (ages 8 - 13 years old). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-018161-12 | Sponsor Protocol Number: SPD503-315 | Start Date*: 2010-12-23 | ||||||||||||||||||||||||||
Sponsor Name:Shire Development Inc | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol... | ||||||||||||||||||||||||||||
Medical condition: Attention-Deficit/Hyperactive Disorder (ADHD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005452-34 | Sponsor Protocol Number: SPD489-406 | Start Date*: 2013-08-20 | |||||||||||
Sponsor Name:Shire Development LLC | |||||||||||||
Full Title: A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, ... | |||||||||||||
Medical condition: Attention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivity | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) HU (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002844-18 | Sponsor Protocol Number: 04071962 | Start Date*: 2017-01-16 |
Sponsor Name:Medical University of Vienna, Dpt. of Pediatrics | ||
Full Title: Preventive sublingual immunotherapy for house dust mite sensitized preschool children | ||
Medical condition: Patients; children at age 4 years with house dust mite IgE sensitization without allergic disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000853-37 | Sponsor Protocol Number: SCH/07/006 | Start Date*: 2009-01-20 |
Sponsor Name:Sheffield Children's NHS Foundation Trust | ||
Full Title: Botulinum Toxin: an adjunct in limb reconstruction – can it reduce pain and joint complications in the lengthening phase? | ||
Medical condition: The surgery to correct leg & foot deformities in children is a lengthy, & sometimes, difficult procedure. Metal frames are attached to the leg and / or foot and over a period of time the frame is m... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-001466-42 | Sponsor Protocol Number: 17-HPNCL-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVAL | |||||||||||||
Full Title: EFFECTIVENESS OF INTRANASAL DEXMEDETOMIDINE FOR SEDATED AUDITORY BRAINSTEM RESPONSE TESTING | |||||||||||||
Medical condition: Child requiring auditory evaluation in a context of suspicion of deafness, language delay, overall developmental delay, risk factors for hearing loss. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001126-41 | Sponsor Protocol Number: MVDV/MDS-12/2014 | Start Date*: 2015-07-10 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: The effect of transversus abdominis plane block on postoperative analgesia after combined spinal epidural anesthesia for Cesarean delivery. | ||
Medical condition: providing adequate analgesia after cesarean delivery. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-002875-81 | Sponsor Protocol Number: NL58621.041.16 | Start Date*: 2016-10-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Bumetanide for the Autism Spectrum Clinical Effectiveness Trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020020-21 | Sponsor Protocol Number: AN10/9307 | Start Date*: 2011-07-12 |
Sponsor Name:Leeds Teaching Hospitals Trust | ||
Full Title: Comparison of the ED95 dose of 0.075% and 0.1% bupivacaine for labour analgesia in primigravida | ||
Medical condition: Patients pregnant for the first time(primigravida)in early labour requesting epidural analgesia for pain relief. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002726-84 | Sponsor Protocol Number: SHP607-203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Premacure AB | |||||||||||||
Full Title: Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants | |||||||||||||
Medical condition: Chronic Lung Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000046-31 | Sponsor Protocol Number: Omega18-13-03 | Start Date*: 2011-11-29 |
Sponsor Name:The Sahlgrenska Center for Pediatric Ophtalmology Research | ||
Full Title: A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity | ||
Medical condition: Premature male/female infants, <28 gestational weeks at birth with risk of developing retinopathy of prematurity (ROP) | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022383-12 | Sponsor Protocol Number: CCX114157 | Start Date*: 2011-02-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease | |||||||||||||
Medical condition: Subjects with Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Completed) NO (Prematurely Ended) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) ES (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) IT (Completed) SK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.